Inosine pranobex was associated with a reduction in mortality in COVID-19 by over 22%, as reported in a retrospective study utilizing complete health data from the Czech national registry

Veselý et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2026.108519, Mar 2026
Early treatmentRetrospective · 127,038 patients · Mar 2020 – Dec 2021
Inosine Pranobex for COVID-19
Outcome
Improvement
Relative Risk · 95% CI
00.511.52+
← Inosine Pranobex
reduces risk
Inosine Pranobex
increases risk →
Lower mortality with inosine pranobex
Not statistically significant · p = 0.11
Retrospective 67,841 inosine pranobex recipients matched 1:2 with 135,682 controls from the Czech national registry, showing significantly reduced COVID-19 mortality with treatment.
Negative control outcome analyses (non-COVID mortality, cardiovascular mortality, external-cause mortality) showed no benefit, suggesting the effect is not purely a healthy-user bias. Authors note that treatment was prescribed preferentially to higher-risk patients, yet recipients still showed lower mortality, which strengthens the apparent benefit but cannot fully exclude unmeasured confounders.
OutcomeImprovementEffect · pTreatmentControl
risk of death 46.3% lower · RR 0.54 · p = 0.11 46.3% lowerRR 0.54p = 0.11 42,346 84,692 treatment 42,346, control 84,692
risk of death 22.0% lower · RR 0.78 · p < 0.001*** 22.0% lowerRR 0.78p < 0.001*** 697 of 42,346 (1.6%) 1,788 of 84,692 (2.1%) treatment 697 of 42,346 (1.6%), control 1,788 of 84,692 (2.1%)pre-omiconNNT 215
risk of death 65.0% lower · RR 0.35 · p < 0.001*** 65.0% lowerRR 0.35p < 0.001*** 32 of 25,495 (0.1%) 181 of 50,990 (0.4%) treatment 32 of 25,495 (0.1%), control 181 of 50,990 (0.4%)omicronNNT 436

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. *** p < 0.001

Veselý et al., 31 Mar 2026, retrospective, Czech Republic, peer-reviewed, 5 authors, study period 1 March, 2020 - 31 December, 2021. Contact: dalibor.vesely@lf3.cuni.cz, veselydalibor@seznam.cz.
Inosine pranobex is an orally administered small-molecule immunomodulator with broad antiviral activity. It enhances natural killer cell cytotoxicity and T-lymphocyte function and promotes Th1-type cytokine responses, thereby augmenting host antiviral defenses.
Abstract: ARTICLE IN PRESS [International Journal of Infectious Diseases xxx (xxxx) xxx](https://doi.org/10.1016/j.ijid.2026.108519) Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: [www.elsevier.com/locate/ijid](http://www.elsevier.com/locate/ijid) Inosine pranobex was associated with a reduction in mortality in COVID-19 by over 22%, as reported in a retrospective study utilizing complete health data from the Czech national registry Dalibor Veselý 1 , ∗ , Václav ˇ Capek 2 , Ondˇ rej Šanca 3 , Jiˇ rí Beran 4 , Jiˇ rí Slíva 1 - 1 Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic - 2 Independent researcher - 3 Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic - 4 Department for Tropical, Travel Medicine and Immunization, Institute for Postgraduate Medical Education, Prague, Czech Republic a r t i c l e i n f o Article history: Received 24 August 2025 Revised 17 February 2026 Accepted 28 February 2026 Available online xxx pranobex Keywords: COVID-19 Pandemic Inosine Isoprinosine Mortality Risk factor
DOI record: { "DOI": "10.1016/j.ijid.2026.108519", "ISSN": [ "1201-9712" ], "URL": "http://dx.doi.org/10.1016/j.ijid.2026.108519", "alternative-id": [ "S1201971226001542" ], "article-number": "108519", "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Inosine pranobex was associated with a reduction in mortality in COVID-19 by over 22%, as reported in a retrospective study utilizing complete health data from the Czech national registry" }, { "label": "Journal Title", "name": "journaltitle", "value": "International Journal of Infectious Diseases" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.ijid.2026.108519" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "© 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases." } ], "author": [ { "ORCID": "https://orcid.org/0009-0003-8069-2368", "affiliation": [], "authenticated-orcid": false, "family": "Veselý", "given": "Dalibor", "sequence": "first" }, { "affiliation": [], "family": "Čapek", "given": "Václav", "sequence": "additional" }, { "affiliation": [], "family": "Šanca", "given": "Ondřej", "sequence": "additional" }, { "affiliation": [], "family": "Beran", "given": "Jiří", "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0003-2690-1889", "affiliation": [], "authenticated-orcid": false, "family": "Slíva", "given": "Jiří", "sequence": "additional" } ], "container-title": "International Journal of Infectious Diseases", "container-title-short": "International Journal of Infectious Diseases", "content-domain": { "crossmark-restriction": true, "domain": [ "clinicalkey.com", "clinicalkey.com.au", "clinicalkey.es", "clinicalkey.fr", "clinicalkey.jp", "ijidonline.com", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2026, 3, 31 ] ], "date-time": "2026-03-31T12:06:47Z", "timestamp": 1774958807000 }, "deposited": { "date-parts": [ [ 2026, 3, 31 ] ], "date-time": "2026-03-31T12:06:53Z", "timestamp": 1774958813000 }, "funder": [ { "DOI": "10.13039/100007397", "doi-asserted-by": "publisher", "id": [ { "asserted-by": "publisher", "id": "10.13039/100007397", "id-type": "DOI" } ], "name": "Univerzita Karlova v Praze" } ], "indexed": { "date-parts": [ [ 2026, 4, 1 ] ], "date-time": "2026-04-01T05:30:34Z", "timestamp": 1775021434016, "version": "3.50.1" }, "is-referenced-by-count": 1, "issued": { "date-parts": [ [ 2026, 3 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2026, 3, 1 ] ], "date-time": "2026-03-01T00:00:00Z", "timestamp": 1772323200000 } }, { "URL": "https://www.elsevier.com/legal/tdmrep-license", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2026, 3, 1 ] ], "date-time": "2026-03-01T00:00:00Z", "timestamp": 1772323200000 } }, { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2026, 2, 28 ] ], "date-time": "2026-02-28T00:00:00Z", "timestamp": 1772236800000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S1201971226001542?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S1201971226001542?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "108519", "prefix": "10.1016", "published": { "date-parts": [ [ 2026, 3 ] ] }, "published-print": { "date-parts": [ [ 2026, 3 ] ] }, "publisher": "Elsevier BV", "reference": [ { "DOI": "10.2165/00003495-198632050-00001", "article-title": "Inosine pranobex", "author": "Campoli-Richards", "doi-asserted-by": "crossref", "first-page": "383", "journal-title": "Drugs", "key": "10.1016/j.ijid.2026.108519_bib0001", "volume": "32", "year": "1986" }, { "DOI": "10.1007/s12325-019-00995-6", "article-title": "Inosine pranobex: a key player in the game against a wide range of viral infections and non-infectious diseases", "author": "Sliva", "doi-asserted-by": "crossref", "first-page": "1878", "journal-title": "Adv Ther", "key": "10.1016/j.ijid.2026.108519_bib0002", "volume": "36", "year": "2019" }, { "DOI": "10.3390/v13112246", "article-title": "Inosine pranobex deserves attention as a potential immunomodulator to achieve early alteration of the COVID-19 disease course", "author": "Beran", "doi-asserted-by": "crossref", "first-page": "2246", "journal-title": "Viruses", "key": "10.1016/j.ijid.2026.108519_bib0003", "volume": "13", "year": "2021" }, { "DOI": "10.1146/annurev-immunol-032712-100001", "article-title": "Control of human viral infections by natural killer cells", "author": "Jost", "doi-asserted-by": "crossref", "first-page": "163", "journal-title": "Annu Rev Immunol", "key": "10.1016/j.ijid.2026.108519_bib0004", "volume": "31", "year": "2013" }, { "DOI": "10.1016/j.intimp.2016.11.023", "article-title": "Inosine acedoben dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: a clinical trial supporting anti-viral indications", "author": "Rumel Ahmed", "doi-asserted-by": "crossref", "first-page": "108", "journal-title": "Int Immunopharmacol", "key": "10.1016/j.ijid.2026.108519_bib0005", "volume": "42", "year": "2017" }, { "DOI": "10.1002/eji.201847948", "article-title": "Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression", "author": "McCarthy", "doi-asserted-by": "crossref", "first-page": "130", "journal-title": "Eur J Immunol", "key": "10.1016/j.ijid.2026.108519_bib0006", "volume": "50", "year": "2020" }, { "DOI": "10.3390/pathogens9121055", "article-title": "Inosine pranobex significantly decreased the case-fatality rate among PCR positive elderly with SARS-CoV-2 at three nursing homes in the Czech Republic", "author": "Beran", "doi-asserted-by": "crossref", "first-page": "1055", "journal-title": "Pathogens", "key": "10.1016/j.ijid.2026.108519_bib0007", "volume": "9", "year": "2020" }, { "article-title": "Efficacy and safety of inosine pranobex in COVID-19 patients: a multicenter phase 3 randomized double-blind, placebo-controlled trial", "author": "C", "journal-title": "Adv Ther", "key": "10.1016/j.ijid.2026.108519_bib0008", "volume": "5", "year": "2022" }, { "DOI": "10.1016/j.ijid.2024.01.017", "article-title": "Case fatality rates of COVID-19 during epidemic periods of variants of concern: a meta-analysis by continents", "author": "Xia", "doi-asserted-by": "crossref", "journal-title": "Int J Infect Dis", "key": "10.1016/j.ijid.2026.108519_bib0009", "volume": "141", "year": "2024" }, { "DOI": "10.3389/fpubh.2022.884121", "article-title": "Risk of SARS-CoV-2 reinfection 18 months after primary infection: population-level observational study", "author": "Flacco", "doi-asserted-by": "crossref", "journal-title": "Front Public Health", "key": "10.1016/j.ijid.2026.108519_bib0010", "volume": "10", "year": "2022" }, { "DOI": "10.1038/s41586-020-2918-0", "article-title": "Age-specific mortality and immunity patterns of SARS-CoV-2", "author": "O’Driscoll", "doi-asserted-by": "crossref", "first-page": "140", "journal-title": "Nature", "key": "10.1016/j.ijid.2026.108519_bib0011", "volume": "590", "year": "2021" }, { "DOI": "10.1136/bmj.m4509", "article-title": "Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study", "author": "Pastor-Barriuso", "doi-asserted-by": "crossref", "first-page": "m4509", "journal-title": "BMJ", "key": "10.1016/j.ijid.2026.108519_bib0012", "volume": "371", "year": "2020" }, { "DOI": "10.1016/j.ijid.2020.07.029", "article-title": "Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis", "author": "Zhou", "doi-asserted-by": "crossref", "first-page": "47", "journal-title": "Int J Infect Dis", "key": "10.1016/j.ijid.2026.108519_bib0013", "volume": "99", "year": "2020" }, { "DOI": "10.3389/fmed.2021.588013", "article-title": "Chronic diseases as a predictor for severity and mortality of COVID-19: a systematic review with cumulative meta-analysis", "author": "Geng", "doi-asserted-by": "crossref", "journal-title": "Front Med", "key": "10.1016/j.ijid.2026.108519_bib0014", "volume": "8", "year": "2021" }, { "key": "10.1016/j.ijid.2026.108519_bib0015", "unstructured": "Šanca O, Jarkovský J, Klika P, Davidová H, Klimeš D, Mužík J, et al. Přehled vykázaných tříznakových diagnóz dle MKN-10. 2024. https://www.nzip.cz/clanek/1760-prehled-vykazane-triznakove-diagnozy-mkn-10-nrhzs-datovy-souhrn [accessed 30 April 2025]." }, { "DOI": "10.1093/eurheartj/ehaa433", "article-title": "Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study", "author": "Gao", "doi-asserted-by": "crossref", "first-page": "2058", "journal-title": "Eur Heart J", "key": "10.1016/j.ijid.2026.108519_bib0016", "volume": "41", "year": "2020" }, { "DOI": "10.2337/dci21-0001", "article-title": "Diabetes and COVID-19: population impact 18 months into the pandemic", "author": "Gregg", "doi-asserted-by": "crossref", "first-page": "1916", "journal-title": "Diabetes Care", "key": "10.1016/j.ijid.2026.108519_bib0017", "volume": "44", "year": "2021" }, { "DOI": "10.1016/j.medcli.2020.12.017", "article-title": "Coronary heart disease and COVID-19: a meta-analysis", "author": "Liang", "doi-asserted-by": "crossref", "first-page": "547", "journal-title": "Med Clín", "key": "10.1016/j.ijid.2026.108519_bib0018", "volume": "156", "year": "2021" }, { "DOI": "10.1016/j.ajem.2020.07.009", "article-title": "Effect of heart failure on the outcome of COVID-19 — a meta analysis and systematic review", "author": "Yonas", "doi-asserted-by": "crossref", "first-page": "204", "journal-title": "Am J Emerg Med", "key": "10.1016/j.ijid.2026.108519_bib0019", "volume": "46", "year": "2021" }, { "DOI": "10.20892/j.issn.2095-3941.2020.0559", "article-title": "Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants", "author": "Yang", "doi-asserted-by": "crossref", "first-page": "298", "journal-title": "Cancer Biol Med", "key": "10.1016/j.ijid.2026.108519_bib0020", "volume": "18", "year": "2021" }, { "DOI": "10.1111/jce.14770", "article-title": "Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19", "author": "Peltzer", "doi-asserted-by": "crossref", "first-page": "3077", "journal-title": "J Cardiovasc Electrophysiol", "key": "10.1016/j.ijid.2026.108519_bib0021", "volume": "31", "year": "2020" }, { "DOI": "10.1016/j.jstrokecerebrovasdis.2020.104949", "article-title": "Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19–systematic review, meta-analysis, and meta-regression", "author": "Pranata", "doi-asserted-by": "crossref", "journal-title": "J Stroke Cerebrovasc Dis", "key": "10.1016/j.ijid.2026.108519_bib0022", "volume": "29", "year": "2020" }, { "DOI": "10.1038/s41598-023-36208-y", "article-title": "Anemia as a risk factor for disease progression in patients admitted for COVID-19: data from a large, multicenter cohort study", "author": "Veronese", "doi-asserted-by": "crossref", "first-page": "9035", "journal-title": "Sci Rep", "key": "10.1016/j.ijid.2026.108519_bib0023", "volume": "13", "year": "2023" }, { "DOI": "10.1097/MCP.0000000000000834", "article-title": "Chronic obstructive pulmonary disease and COVID-19: interrelationships", "author": "Singh", "doi-asserted-by": "crossref", "first-page": "76", "journal-title": "Curr Opin Pulm Med", "key": "10.1016/j.ijid.2026.108519_bib0024", "volume": "28", "year": "2022" }, { "DOI": "10.1016/j.cpcardiol.2021.101007", "article-title": "Peripheral artery disease and COVID-19 outcomes: insights from the Yale DOM-CovX registry", "author": "Smolderen", "doi-asserted-by": "crossref", "journal-title": "Curr Probl Cardiol", "key": "10.1016/j.ijid.2026.108519_bib0025", "volume": "47", "year": "2022" }, { "DOI": "10.1038/s41598-022-06276-7", "article-title": "Mortality and readmission rates among hospitalized COVID-19 patients with varying stages of chronic kidney disease: a multicenter retrospective cohort", "author": "Appelman", "doi-asserted-by": "crossref", "first-page": "2258", "journal-title": "Sci Rep", "key": "10.1016/j.ijid.2026.108519_bib0026", "volume": "12", "year": "2022" }, { "DOI": "10.1007/s11684-020-0822-5", "article-title": "Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection", "author": "Tan", "doi-asserted-by": "crossref", "first-page": "746", "journal-title": "Front Med", "key": "10.1016/j.ijid.2026.108519_bib0027", "volume": "14", "year": "2020" }, { "DOI": "10.1016/j.isci.2022.103743", "article-title": "Immunity to SARS-CoV-2 up to 15 months after infection", "author": "Marcotte", "doi-asserted-by": "crossref", "journal-title": "iScience", "key": "10.1016/j.ijid.2026.108519_bib0028", "volume": "25", "year": "2022" }, { "article-title": "Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells", "author": "Cohen", "journal-title": "Cell Rep Med", "key": "10.1016/j.ijid.2026.108519_bib0029", "volume": "2", "year": "2021" }, { "DOI": "10.1056/NEJMoa2118691", "article-title": "Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection", "author": "Hall", "doi-asserted-by": "crossref", "first-page": "1207", "journal-title": "N Engl J Med", "key": "10.1016/j.ijid.2026.108519_bib0030", "volume": "386", "year": "2022" }, { "DOI": "10.1016/j.envres.2022.112911", "article-title": "SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity", "author": "Pilz", "doi-asserted-by": "crossref", "journal-title": "Env Res", "key": "10.1016/j.ijid.2026.108519_bib0031", "volume": "209", "year": "2022" }, { "DOI": "10.1186/s12879-022-07418-y", "article-title": "SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis", "author": "Ssentongo", "doi-asserted-by": "crossref", "first-page": "439", "journal-title": "BMC Infect Dis", "key": "10.1016/j.ijid.2026.108519_bib0032", "volume": "22", "year": "2022" }, { "DOI": "10.1016/S0140-6736(22)00152-0", "article-title": "Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression", "author": "Feikin", "doi-asserted-by": "crossref", "first-page": "924", "journal-title": "Lancet", "key": "10.1016/j.ijid.2026.108519_bib0033", "volume": "399", "year": "2022" }, { "DOI": "10.1001/jama.2021.19499", "article-title": "Association between mRNA vaccination and COVID-19 hospitalization and disease severity", "author": "Tenforde", "doi-asserted-by": "crossref", "first-page": "2043", "journal-title": "JAMA", "key": "10.1016/j.ijid.2026.108519_bib0034", "volume": "326", "year": "2021" }, { "DOI": "10.1016/S0140-6736(20)32661-1", "article-title": "AZ - safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK", "author": "Voysey", "doi-asserted-by": "crossref", "first-page": "99", "journal-title": "Lancet", "key": "10.1016/j.ijid.2026.108519_bib0035", "volume": "397", "year": "2021" }, { "DOI": "10.1056/NEJMoa2101544", "article-title": "Jansen safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19", "author": "Sadoff", "doi-asserted-by": "crossref", "first-page": "2187", "journal-title": "N Engl J Med", "key": "10.1016/j.ijid.2026.108519_bib0036", "volume": "384", "year": "2021" }, { "key": "10.1016/j.ijid.2026.108519_bib0037", "unstructured": "Ewopharma International, s.r.o. Isoprinosine 500 mg tablety SmPC. State Institute for Drug Control (SÚKL); 2019. https://prehledy.sukl.cz/prehledy/v1/dokumenty/12916 [accessed 10 August 2025]." }, { "key": "10.1016/j.ijid.2026.108519_bib0038", "unstructured": "Themis Medicare Limited. Viralex SmPC. Rwanda Food and Drug Authority; 2024. https://rwandafda.gov.rw/wp-content/uploads/2025/04//VIRALEX-InosinePranobex500mgTablets-SmPC.pdf [accessed 10 August 2025]." }, { "DOI": "10.1016/S1473-3099(22)00507-2", "article-title": "Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study", "author": "Wong", "doi-asserted-by": "crossref", "first-page": "1681", "journal-title": "Lancet Infect Dis", "key": "10.1016/j.ijid.2026.108519_bib0039", "volume": "22", "year": "2022" } ], "reference-count": 39, "references-count": 39, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S1201971226001542" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Inosine pranobex was associated with a reduction in mortality in COVID-19 by over 22%, as reported in a retrospective study utilizing complete health data from the Czech national registry", "type": "journal-article", "update-policy": "https://doi.org/10.1016/elsevier_cm_policy" }